Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides

Dermatologic Surgery

Volumn 29, Issue 1, 2003, Pages 7-13

  Matarasso, Seth L ^a,b   Baumann, Leslie ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ARTICLE; CANTHAL RHYTIDES; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSTONIA; FEMALE; HUMAN; ORBICULARIS OCULI MUSCLE; PARALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SKIN DISEASE; TREATMENT OUTCOME;

ADULT; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DOUBLE-BLIND METHOD; FACIAL MUSCLES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEUROMUSCULAR AGENTS; SKIN AGING; TREATMENT OUTCOME;

EID: 0037237889     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2003.29017.x     Document Type: Article

References (39)

1. ASAPS 2000 Statistics on Cosmetic Surgery. New York: Am Society Aes Plast Surg, March 2001.
2. Matarasso SL. Botox therapy for facial rejuvenation. Skin Aging 1998;5:134-6.
3. Simpson LL. Peripheral actions of the botulinum toxins. In: Simpson LL, ed. Botulinum Neurotoxin and Tetanus Toxin. New York: Academy Press, 1989:153-78.
4. Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999;103:701-13.
5. Blitzer A, Brin MF, Keen MF, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018-22.
6. Guyuron B, Huddleston SW. Aesthetic indications of botulinum toxin injection. Plast Reconstr Surg 1994;93:913.
7. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report of partial lip ptosis following injections into the lateral canthal rhytides. Plast Reconstr Surg 2001;108:208-14.
8. Edelstein C, Shorr N, Jacobs J, Balch K, Goldberg R. Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998;24:1208-12.
9. Carruthers JD, Carruthers A. Botulinum toxin and laser resurfacing for lines around the eyes. In: Blitzer A, Binder WJ, Boyd B, Carruthers A., eds. Management of Facial Lines and Wrinkles. Philadelphia: Lippincott Williams & Wilkins, 2000:315-32.
10. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43:249-59.
11. Shone CC. Clostridium botulinum neurotoxins, their structures and modes of action. In: Watson ED, ed. Natural Toxicants in Foods. Chichester: Ellis Harwood, 1986:11-57.
12. Coffield JA, Bakry N, Zhang RD, et al. In vitro characterization of botulinum toxins type A, C, and D action on human tissues: combined electrophysiologic, pharmacologic, and molecular approaches. J Pharmacol Exp Ther 1997;280:1489-99.
13. Humeau Y, Doussau F, Grant NJ., et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000;82:42746.
14. Brin MF. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In: Blitzer RA, Binder WJ, Boyd B, Carruthers A, eds. Management of Facial Lines and Wrinkles. Philadelphia: Lippincott Williams & Wilkins, 1999:279-302.
15. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-93.
16. Brashear A, Lew MF, Dykstra DD., et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46.
17. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of Neurobloc (botulinmn toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8.
18. Package Insert Botox (botulinum toxin type A)Package Insert Botox (botulinum toxin type A) Purified Neurotoxin Complex. Irvine, CA: Allergan Inc., 1995.
19. Lowe NJ. Botulinum toxin type A for facial rejuvenation. Dermatol Surg 1998;24:1216-8.
20. Carruthers A, Carruthers JD. Cosmetic Uses of Botulinum A Exotoxin: Advance Dermatology. St. Louis: Mosby Yearbook, 1997:325-48.
21. Matarasso SL. Update on the aesthetic uses of botulinum A neurotoxin in facial rejuvenation. Curr Prob Dermatol 2001;13:46-52.
22. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997;49:189-94.
23. Borodic G, Johnson E, Goodrough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-9.
24. Package Insert Myobloc (botulinum toxin type B). South San Francisco: Elan Pharmaceuticals, Inc., 2000.
25. Carruthers A, Carruthers JD. 1999 Toxins: new information about the botulinum neurotoxins. Dermatol Surg 2000;26:174-6.
26. Matarasso SL. Decreased tear expression with an abnormal Schirmer's test following botulinum toxin for the treatment of lateral canthal rhytides. Dermatol Surg 2002;28:1-5.
27. Wieder JM, Moy RL. Understanding botulinum toxin: surgical anatomy of the frown, forehead, and periocular region. Dermatol Surg 1998;24:1172-4.
28. Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998;24:1249-54.
29. Callaway JE, Oregozo T, Gore N, et al. Myobloc, Botulinum Toxin Type, B Injectable Solution. South San Francisco: Elan Pharmaceuticals, Inc., 2001.
30. Baumann L. Botulinum toxin type B starts as strong as alternative. Dermatol Times 2001:48.
31. Alare M, Dover JS. Arndt KA, Pain associated with injection of botulinum A exotoxin reconstituted using saline with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002;138:5104.
32. Sadick N. Personal Communication: International. Guadalajara: Society for Dermatologic Surgery, 2001.
33. Arezzo JC, Litwak MS, Caputo FA, Shopp GM, Meyer KE. Paralytic effects of BoNT-A versus BoNT-B in injected and noninjected muscles. In: Am Acad Pain Med, February 2001, Miami Beach, FL. In Scientific Compendium 9-13, Myobloc, Botulinum Toxin Type B Injectable Solution. South San Francisco: Elan Pharmaceuticals, 2001.
34. Matarasso SL, Matarasso A, Brandt FS, et al. Botulinum-A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999;103:645-55.
35. Heckmann M, Ceballos-Baumann A, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;344:488-93.
36. Heckmann M, Breit S, Ceballos-Baumann A. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 1999;41:987-90.
37. Donoghue S, Corn T. Duration of effectiveness of Neurobloc (Botulinum Toxin Type B) in patients with cervical dystonia. In: Scientific Compendium, 31-35, Myobloc, Botulinum Toxin Type B Injectable Solution. South San Francisco: Elan Pharmaceuticals, 2001.
38. Spencer JM. Cosmetic uses of botulinum toxin type B. Cosm Dermatol 2002;15:11-4.
39. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000;12:22-S28.